Multicenter observational study on re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab.

Tomomi Kashiwada,Hiroshi Saeki,Yoshikazu Uenosono,Akitaka Makiyama,Masaaki Iwatsuki,Yukiya Narita,Hironaga Satake,Yoshiko Matsuda,Hideto Sonoda,Eiji Oki,Yoshihiko Maehara

Multicenter observational study on re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab.

2018

Tomomi Kashiwada
Hiroshi Saeki
Yoshikazu Uenosono
Akitaka Makiyama
Masaaki Iwatsuki
Yukiya Narita
Hironaga Satake
Yoshiko Matsuda
Hideto Sonoda
Eiji Oki
Yoshihiko Maehara

4038Background: Addition of trastuzumab to cisplatin and fluoropyrimidine-based doublet chemotherapy is the standard first-line treatment for patients with human epidermal growth factor receptor 2 ...

Keywords:

Recurrent gastric cancer
Refractory
Trastuzumab
Observational study
Oncology
Pathology
Internal medicine
Medicine
Human Epidermal Growth Factor Receptor 2
in patient
Chemotherapy
Cisplatin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations